Please assess the completion status of the following clinical trial:

Trial Title: Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed written informed consent.~2. Age ≥ 18 years old (or minimum age based upon local regulations)~3. Unresectable locally advanced or metastatic histologically proven HER2+ gastroesophageal junction (GEJ) or gastric cancer. Gastric Cancer Expansion Phase will include only gastric cancer patients with 3+ HER2 positivity.~4. HER2+ as 3+ (as defined in AJCC staging manual 8th edition) by IHC or in-situ hybridation (ISH) amplified.~5. Have received prior treatment with trastuzumab.~6. Have received treatment with at least one or more lines of cytotoxic chemotherapy in the metastatic setting.~7. Resolution of chemotherapy, immunotherapy or radiation-related toxicities.~8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~9. Life expectancy ≥ 12 weeks.~10. Measurable disease as per RECIST 1.1 criteria.~Exclusion Criteria:~1. Patients with symptomatic central nervous system (CNS) metastases.~2. Patients with any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, atopic dermatitis, or psoriasis not requiring systemic treatment.~3. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.~4. Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 3 weeks prior to the initiation of study drug.~5. Treatment with radiation therapy within 3 weeks prior to the initiation of study drug administration.~6. Treatment with corticosteroids (≥10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration.~7. History of clinically-significant cardiovascular disease.~8. Clinically-significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation.~9. History of (non-infectious) pneumonitis that required steroids or presence of active pneumonitis~10. Clinically-significant gastrointestinal disorders, such as perforation, gastrointestinal bleeding, or diverticulitis.~11. Evidence of active viral, bacterial, or systemic fungal infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Margetuximab 10 mg/kg plus pembrolizumab 200 mg (Type: EXPERIMENTAL): margetuximab administered in combination with pembrolizumab
- Cohort 2: Margetuximab 15 mg/kg plus pembrolizumab 200 mg (Type: EXPERIMENTAL): margetuximab administered in combination with pembrolizumab

Based on this trial design, predict the completion outcome and termination type (if applicable).